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Abstract 
On 20 February 2020, the Institute for Clinical and Economic Review (ICER) released its draft evidence report to establish the value of 
innovative therapies in the treatment of cystic fibrosis. Following its usual practice, ICER contracted with an outside group to construct 
a value assessment framework, in this case a microsimulation model, to generate value claims.  The primary outcomes for value claims 
were incremental cost-per-QALY simulations for four target cystic fibrosis populations. The value assessment, in common with the same 
model applied earlier by ICER in cystic fibrosis, recommended substantial price discounts based on arbitrary threshold cost-per-QALY 
values. Unfortunately, the entire exercise, as detailed in previous commentaries in INNOVATIONS in Pharmacy is essentially a waste of 
time. Not only is the reference case model presented by ICER only one of a multiverse of other models, all driven by a selective 
application of model structure and assumptions, but the fact that the utilities that are applied to hypothetical time spent in different 
disease stages to modeled QALYs and lifetime cost-per-QALY claims fail to meet fundamental measurement axioms: they are ordinal 
manifest scores. Applied to target cystic fibrosis target patient groups, the modeled claims are meaningless. From the manufacturer’s 
perspective, in this case Vertex Pharmaceuticals who have developed all the cystic fibrosis therapies ‘modeled’ by the ICER contractor, 
their response to ICER claims should be to reject them out of hand; the constructs are imaginary and the outcome claims nonsense.  
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Introduction 
The construction of assumption driven imaginary worlds to 
support incremental cost-per-QALY claims for pricing and 
access recommendations is the hallmark of the Institute for 
Clinical and Economic Review’s (ICER) business model. ICER has 
issued two evidence reports on cystic fibrosis. The first report, 
a final evidence report was released in 2018; the second report, 
a draft evidence report, on 20 February 2020 1 2. The focus of 
this commentary is on the second report. Even so, this analysis 
of the manifest failings of the second report apply equally to 
the first report: neither the economic model nor the 
recommendations for pricing and access should be taken 
seriously. Indeed, it is worth noting that following the release 
of the first evidence report Vertex Pharmaceuticals, whose 
drugs featured in ICER’s modeled ‘analysis’, Kalydeco 
(ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symdeko 
(tezacaftor/ivacaftor and ivacaftor), issued a strong 
condemnation of the ICER methodology, ‘a flawed scientific 
methodology’, and a ‘sham’ evaluation process, where 
conclusions were agenda-driven and pre-ordained 3. In the 
second report it once again it is only Vertex cystic fibrosis 
therapies that are considered. These include the therapies 
considered for modeling in the first report but with the addition 
of the  Trikafta  (elexacaftor/tezacaftor/ivacaftor) combination.  
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The ICER model for the 2020 draft evidence report was an 
updated version of their previous imaginary microsimulation 
model.  The modeling objective was to estimate the 
hypothetical lifetime effectiveness and cost-effectiveness of 
CFTR modulator treatments plus best supportive care for cystic 
fibrosis patients in the specific imaginary model framework. 
The primary health outcome was quality adjusted life years 
(QALYs) utilizing EQ-5D-3L utilities. Other lifetime horizons 
outcomes were life years, equal value of life years gained and 
lifetime number of acute pulmonary exacerbations. There was 
no expectation that any of these fabricated outcomes could be 
evaluated empirically given the lifetime framework. These 
imaginary outcomes were discounted, along with costs, in the 
base case model at 3%.  
 
The lifetime microsimulation model created an imaginary value 
assessment for four possible therapeutic options  for four cystic 
fibrosis populations. : (i) patients who are candidates for 
Kalydeco monotherapy; (ii) patients who are homozygous for 
the F508del mutation; (iii) patients who are heterozygous for 
the F508del mutation; and (iv) patients who are heterozygous 
with minimal function mutation. The primary model variable 
was FEV1%, modeled as a continuous variable to capture the 
effect of the CFTR modulator drugs. Imaginary patients in the 
model are simulated to accumulate life years, QALYs and costs. 
EQ-5D-3L ordinal utility values were assigned to ppFEVi status 
to generate QALYs per year and cumulate them over the 
lifetime of the patient. 
 
The base case incremental cost-per-QALY ‘results’ (against best 
supportive care) for each of the patient models are, of course, 
imaginary and not for empirical assessment (i.e., hypothesis 
testing). We have to take them at face value; or reject them 
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accordingly. For each population simulated estimates are 
presented for total QALYs, total life years and equal value life 
years. Imaginary QALY gains are modest, ranging from 4 to 7 
years. Incremental simulated lifetime costs are substantial 
ranging from $5.5 million to $7.0 million dollars, set against best 
supportive care. Consequent estimates of imaginary cost-per-
QALY gained are, unsurprisingly, substantial. These range from 
$818,000 for Trikafta plus best supportive care to $1,060,000 
for both  Kalydeco plus best supportive care and Symdeko plus 
best supportive care. Inevitably, these lead ICER to conclude 
that while the therapies clearly have substantial clinical benefits 
(which we knew anyway), this can only be realized if there are 
substantial price discounts. According to the imaginary 
microsimulation, a discount of 35 – 51% would be necessary to 
reach a cost-effectiveness threshold of $500,000/QALY for 
Kalydeco and Symdeko (as they classify as a rare disease target) 
while discounts of 65 – 66% would be necessary for Trikafta to 
reach a cost-effectiveness threshold of $200,000/QALY. Again, 
caution is in order as these are entirely assumption driven 
imaginary claims; alternative models could lead to quite 
different imaginary conclusions. 
 
Nonsense on Stilts 
A recent commentary in INNOVATIONS in PHARMACY reviewed 
the latest ICER VAF to be applied over the period 2020 to 2023 
4. The commentary concluded that the VAF failed to meet the 
standards of normal science; it was considered pseudoscience.  
The principal reason for the ICER VAF failing the demarcation 
criteria between science and pseudoscience (or pure bunk) was 
its rejection of modeled claims that allow empirical evaluation. 
At the same time, the ICER VAF fails the standards for 
fundamental measurement 5. It applies utilities which are 
manifest scores, they have ordinal rather than interval scale 
properties. This means that the consequent QALY and cost-per 
QALY estimates are meaningless. The consequences are, for 
products in cystic fibrosis, that conclusions regarding estimated 
value and proposals for lifetime cost-per-QALY, with 
consequent recommendations for price discounting are 
unsupportable. They are an unnecessary illusory distraction, 
irrespective of the degree of precision presented.  
 
The purpose of this commentary is to build on the analyses and 
arguments presented in previous commentaries, notably the 
review of the ICER 2020-2023 VAF, to make the case for 
rejecting the draft evidence report on cystic fibrosis.  The 
commentary starts with a brief restatement of the role of 
normal science as a process of discovering new facts; not 
recycling old assumptions. This is followed by a rejection of 
ICER’s fabrication of an imaginary future sickle cell treating 
environment as simply one of any number that could be created 
with varying assumptions. After all, the accepted framework in 
health technology assessment which ICER accepts is to reject 
hypothesis testing in favor of ‘approximate information’ 
(whatever that means for an unknown future) 6. 
 
Given ICER’s emphasis on QALYs and the fabrication of 
incremental cost-per-QALY claims, the next step is to point out 
the failure of ICER to grasp that if utility scores are to be applied 
to estimate time in disease states, then they have to meet the 
fundamental axioms of measurement theory: invariance of 
comparisons and sufficiency. They have to reflect an underlying 
construct of relevance to the target patient population with 
unidimensional and interval scoring properties. The EQ-5D 
utilities that ICER relies upon in fabricating claims in cystic 
fibrosis do not meet these standards. The QALYs are nonsense. 
 
Finally, we point to the importance of constructing claims for 
treatment response within disease areas; not utilizing a generic 
health related quality of life construct (the EQ-5D) that captures 
a limited number of symptoms and ordinal responses. The case 
made here is for a latent needs-based construct, where the 
instrument reflects the needs of patients in cystic fibrosis and, 
if required, a separate instrument for the needs of caregivers. 
These should meet Rasch standards 7. This is an unexceptional 
requirement that has been in place for 60 years in the 
application of Rasch Measurement Theory (RMT) to instrument 
development.  
 
The Standards of Normal Science 
The requirement for testable hypotheses in the evaluation and 
provisional acceptance of claims made for pharmaceutical 
products and devices is unexceptional. Since the 17th century, it 
has been accepted that if a research agenda is to advance, if 
there is to be an accretion of knowledge, there has to be a 
process of discovering new facts. By the 1660s, the scientific 
method, following the seminal contributions of Bacon, Galileo, 
Huygens and Boyle, had been clearly articulated by associations 
such as the Academia del Cimento in Florence (1657) and the 
Royal Society in England (founded 1660; Royal Charter 1662) 
with their respective mottos Provando e Riprovando (prove and 
again prove) and nullius in verba (take no man’s word for it) 8.  
By the early 20th century, standards for empirical assessment 
were put on a sound methodological basis by Popper (Sir Karl 
Popper 1902-1994) in his advocacy of a process of ‘conjecture 
and refutation 9 10 .  Hypotheses or claims must be capable of 
falsification; indeed, they should be framed in such a way that 
makes falsification likely.  
Although Popper’s view on what demarcates science (e.g., 
natural selection) from pseudoscience (e.g., intelligent design) 
is now seen as an oversimplification involving more than just 
the criteria of falsification, the demarcation problem remains 
11.  Certainly, there are different ways of doing science but what 
all scientific inquiry has in common is the ‘construction of 
empirically verifiable theories and hypotheses’. Empirical 
testability is the ‘one major characteristic distinguishing science 
from pseudoscience’; theories must be tested against data. We 
can only justify our preference for a theory by continued 
evaluation and replication of claims. This applies in cystic 
fibrosis just as it does in other therapies. Constructing 
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imaginary worlds, even if the justification is that they are ‘for 
information’ is, to use Bentham’s (Jeremy Bentham 1748-1832) 
memorable phrase ’nonsense on stilts’. If there is a belief, as 
subscribed to by ICER, in the sure and certain hope of 
constructing imaginary worlds, to drive formulary and pricing 
decisions, then it needs to be made clear that this is a belief that 
lacks scientific merit. 
 
Assumptions 
The ICER claim to fame is the ability to construct or fabricate an 
imaginary world that sets the stage for value impact over 10, 20 
or 30 years in the future. In the cystic fibrosis model of the 
therapies offered by Vertex Pharmaceuticals, the number of 
assumptions made to support the microsimulations across the 
four patients groups is truly awesome; some come from the 
literature, others are pure guesswork. Unfortunately, even if an 
assumption driving the imaginary value assessment framework 
is defended by appealing to the literature (including pivotal 
clinical trials) the effort is wasted. 
 
The point, and this goes back to Hume’s (David Hume 1711 – 
1776) induction problem, is that we cannot ask clients in health 
care to believe in models constructed on the belief that prior 
assumptions will hold into the future. It is logically indefensible: 
it cannot be ‘established by logical argument, since from the 
fact that all past futures have resembled past pasts, it does not 
follow that all future futures will resemble future pasts’ 12.  
 
Utilities and QALYs 
Quality adjusted life years (QALYs) can only survive if the 
measure is credible, evaluable and replicable. The QALY 
constructed by ICER in the cystic fibrosis model meets none of 
these criteria. The concept of a QALY is not new; it goes back 
some 40 plus years with the notion of combining time spent in 
a disease state with some multiplicative ‘score’ on a  required 
interval scale of 0 to 1 (death to perfect health),  Combining the 
two, multiplying time by utility is assumed to produce a QALY. 
In the ICER imaginary cystic fibrosis world these are combined 
to produce QALYs for the modeled life span. 
 
Unfortunately, creating a QALY is a mathematically meaningless 
operation. An ordinal scale does not have the required 
fundamental measurement properties. The implications are 
obvious: any attempt to generate an incremental cost-per-
QALY model makes no sense. 
 
HRQoL versus QoL 
It should be remembered that the EQ-5D is a health related 
quality of life (HRQoL) measures. It comprises 5 symptoms 
(select by an expert panel) and 3 response levels for each 
symptom (the EQ-5D-3L) or five response levels (the EQ-5D-5L). 
The latter is considered more responsive, but is for all intents 
and purposes a different system as it yields quite different 
‘utility’ or manifest score profiles.  
 
The fundamental weakness is that HRQoL symptom/response 
instruments have only a tenuous, if any, link to a latent 
construct. They, in fact, represent a mishmash of possible 
health constructs, where each symptom category might 
represent a latent construct. It is an operational measure, not 
one that bears even a limited relationship to a patient-centric 
measure of QoL. 
 
Since the early 1990s, increasing attention has been given to 
QoL versus symptom and response characterizations of HRQoL 
in evaluating the benefit to patients of innovative therapies: the 
needs fulfilment model 13. Rather than imposing a series of 
potential symptoms and responses, the needs approach starts 
from a simple premise: the focus should be on QoL as a single 
latent construct; one which is disease specific (and specific to 
patients and caregivers) which is defined in terms of the needs 
of target groups. If health and disease status are the principal 
driver of ‘good health’ in QoL, then we have to identify those 
needs and devise an instrument that captures those needs in a 
single index with interval properties for target patient and 
caregiver groups.  This is achieved by the application of Rasch 
measurement theory (RMT) in instrument development to give 
a single index with unidimensional properties; an index that 
meets standards for fundamental measurement 14 .  
 
HRQoL in Cystic Fibrosis 
This does not mean that ICER is not aware of disease specific 
instruments in cystic fibrosis. Reference is made to probably the 
most widely used instrument, the Cystic Fibrosis Questionnaire 
(CFQ) 15. In the revised version (CFQ-R) there are three versions: 
adolescents and adults, children and parents. The instrument, 
adolescent and adult version, has 44 items on 12 generic and 
disease specific scales with a composite single score (0 – 100 
scale).  
 
Unfortunately, while the CTQ meets classical test theory 
criteria, it does not exhibit interval scaling properties and does 
not consider a broader QoL needs framework in instrument 
development. The scale only captures manifest scores. Once 
again, we find an instrument that is widely used but where 
those using it are not aware of its lack of fundamental 
measurement properties. This criticism applies across the 
board to the majority of patient recorded  outcome (PRO) 
instruments. Unless there has been a review of Rasch standards 
with possible recalibration, including exclusion, of items, then a 
PRO instrument must be assumed not to meet RMT standards.   
 
Creating Ordinal Utilities for Approximate Information 
The starting point for the ICER imaginary QALY creation is a 
study by Schector et al which ‘creates’ utility scores for health 
states defined by FEV1% 16. The basis for this exercise is a study 
by Bradley et al which reported for a UK cystic fibrosis 
population 17. This study produced three EQ-5D scores 
corresponding to: (i) 0.85 no current pulmonary events ; (ii) 
0.79 mild (no hospitalizations) pulmonary exacerbation; and 
(iii) 0.60 severe (hospitalization) pulmonary exacerbations. 
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Apparently, these correlate well with the ordinal scores of the 
CTQ. Once again, these EQ-5D-3L ‘scores’ lack interval 
measurement properties; we can only rank them as the 
difference between the ‘scores’ has no meaning.  
 
Nevertheless, in defiance of the axioms of fundamental 
measurement in a successor study, Tappenden et al translated 
the Bradley et al results and generated estimates of EQ-5D 
based on FEV1%: FEV1 > 70% EQ-5D = 0.864; FEV1% 40 – 79% = 
EQ-5D 0.810; and FEV1% < 40 = EQ-5D 0.641 18. Despite the fact 
that these EQ-5D ‘estimates’ are still manifest scores, Schector 
et al  went one step further and undertook a linear 
interpolation to ‘predict’ EQ-5D manifest scores for nine FEV1% 
intervals. These scores were used to populate the ICER cystic 
fibrosis model and create imaginary QALYs.  
 
A according to the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR), the 
leaders in health technology assessment have laid down that 
modeled incremental cost-per-QALY claims are the gold 
standard, not for testing hypotheses but to fabricate 
‘approximate information’ 6. Apart from the obvious point that, 
if a formulary committee is faced with competing ‘for 
information’ modeled claims in cystic fibrosis  it will have 
concerns over choosing one set of claims over another, it might 
also have an issue with the meaning of the term  ‘approximate 
information’ defies common sense.  
 
Should we be concerned that claims for innovative therapies in 
a disease such as cystic fibrosis should be the result of 
fabricated and mathematically indefensible QALYs and cost-
per-QALY value assessments? After all, it is only for 
‘approximate information’ not for testing hypotheses. 
However, as Tennant et al point out in their contribution to a 
special supplement in the ISPOR house journal Value in Health 
(2004):  As long as primitive counts and raw scores are routinely 
mistaken for measures by our colleagues in social, educational 
and health research, there is no hope of their professional 
activities ever developing into a reliable useful science 14. 
 
Going Forth 
Certainly, products in cystic fibrosis are considered expensive, 
but this has no stopped manufacturers such as Vertex from 
entering into market access programs in a number of countries 
and health jurisdictions. The ICER model, with its bizarre cost-
per-QALY claims is an unnecessary distraction. It short circuits 
rational, evidence based discussions in formulary decision 
making; discussions which could point to the role of needs-
based patient centric instrumentation to assess claims for 
target cystic fibrosis groups, revised protocols for ongoing 
clinical and observational studies and, overall, a commitment to 
the discovery of new facts. 
 
Science does not advance through the fabrication of imaginary 
worlds built on assumptions, real or imagined. This is echoed by 
Newton (Isaac Newton 1642-1727) with Descartes as his target 
(René Descartes 1596-1650) in saying ‘hypotheses non fingo’ (I 
do not feign hypotheses).  Descartes in Newton’s view had 
‘produced fantastic and untestable ideas, then assumed them 
to be true and used them as building blocks of his philosophy ‘ 
19   
 
Of course, ICER is caught between the proverbial rock and a 
hard place. It has to use a generic utility measure (flawed as it 
is) to support the fabrication of imaginary QALYs; absent a 
generic utility measures (or at least a manifest score on a 0 – 1 
metric), QALYs cannot be modeled and the exercise collapses. 
ICER has no option; it has to use the EQ-5D HRQoL instrument 
even though it may have no relation to the needs of patients 
and caregivers. ICER is then open to continuing criticism that its 
models for value assessment are just ‘nonsense on stilts’. This 
applies to the cystic fibrosis reports as well as to its other 
evidence reports.   The escape for ICER is to propose, after the 
imaginary migraine evidence model has been constructed and 
pricing and access recommendations presented, to suggest a 
move to real world evidence (from imaginary world evidence) 
and a possible disease specific research program. The first step 
seems redundant; but it is the ICER business model. 
 
At launch, we may only have clinical data. This may be sufficient 
to propose cost-outcome claims, but these must be credible, 
evaluable and replicable. If these data points are not to hand 
then, rather than creating an imaginary modeled world, the 
focus should be on claims assessment and feedback to a 
formulary committee. Not, it must be emphasized, a retreat to 
a medieval world where the search for new facts is discouraged; 
subsumed in an acceptance of imaginary and unsupported 
claims for therapy impact and value. 
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